The U.S. Government Accountability Office (GAO)’s survey of state pharmacy regulatory bodies found that since drugs are compounded in a variety of healthcare settings, some data are collected on the number of entities that compound drugs, but less data are available on the volume of compounded drugs. The GAO report also noted that FDA has taken steps to implement its regulatory responsibilities to oversee drug compounding, but states and stakeholder organizations have cited challenges and concerns. Read the GAO report.